Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisAnti-vascular endothelial growth factor for diabetic macular oedemaSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaModes of resistance to anti-angiogenic therapyMolecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersEndogenous and Synthetic Cannabinoids as Therapeutics in Retinal DiseaseInvolvement of B cells in non-infectious uveitisUpdates on the Clinical Trials in Diabetic Macular EdemaSpectral-domain optical coherence tomography for macular edemaTotal Chemical Synthesis of Biologically Active Vascular Endothelial Growth FactorRanibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumabLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edemaTranscriptional regulation of VEGFA by the endoplasmic reticulum stress transducer OASIS in ARPE-19 cellsThe Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsFit for the Eye: Aptamers in Ocular DisordersPost-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degenerationA reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit.Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization.Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.Overview on concepts and applications of Fab antibody fragments.Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization.Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly (D, L-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model.The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularizationComparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative studySafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyA Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration.Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis)Treatment of retinal pigment epithelial detachment with antiangiogenic therapy.Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.
P2860
Q22305863-D1B79133-199E-429D-B061-2916EF6368BEQ24193083-00FFCDBC-5FEB-42A6-9826-F4F34C79D2AEQ24193614-EA03DB55-75FB-475E-B44E-E3240D322009Q24194783-75F107BA-F886-49DC-AADA-FF9480A7C1FEQ24195003-DD085449-9D33-4FD0-A134-498C07082A09Q24201821-0382D353-BD90-4F14-ADBF-B24A033E4FCBQ24202071-03266D5C-20AD-4375-B921-5CB1E3F4D8AEQ24240165-E06C4EB1-1F7D-4105-9129-CA36AA59B223Q24242242-AA125689-F950-43AF-9D98-8DB27E5E3C81Q24608005-E0478A0E-C27D-49A9-A4CD-F579C78015E9Q26765458-DAE9CB61-5B5B-468E-9038-D059567F2F56Q26765576-2B19E2E1-4EDB-49D8-A629-CE5769C8473DQ26766611-93BA1244-6038-409B-8E40-635024833E6DQ26767100-21D74159-2256-4001-BAA8-5E0B36CEFC2DQ27016124-5001FAA7-5047-4257-8216-B90EAC5F00F5Q27670754-74DBBC9C-AAFB-4F58-9FC2-623F3D5FE43CQ28236004-0EF23673-CC6F-4765-812C-5208330F43D1Q28292764-D1A35901-0742-4863-A473-FFAC5C56EECCQ28485361-A3048D1C-BD77-4C09-AD92-69DC4167742FQ28550616-D0C56FE4-0227-43EA-91B1-6C1954F8BF03Q28828283-7E8B36AA-DC8D-4040-8648-B47E21BF56B9Q30438812-03CC335F-1645-427E-A270-E37A00FC5A8AQ30490738-9060CC32-1715-4408-9276-6BD288D1A9A6Q30565636-38722EF8-B49D-4D68-BF54-73831928ACD7Q33358094-A9420486-7424-4F44-B705-06B38F7403E3Q33362774-43FF59E5-42AF-4153-BEE5-BF2997CE54A5Q33397385-3FEE8AD7-D22E-4DCC-9A06-F1DD435849F3Q33411367-0532FCA2-8DD8-41AE-A02B-CAAA7FB6575EQ33493240-6F18FACE-7494-4C62-9B2F-5A9AE185AC22Q33505319-903C21B5-A6FD-4C43-8DEB-A552186B355BQ33518262-A0F7E2CB-457E-4C3A-999A-450F67A6328EQ33520671-6AE62CC3-C33F-4BE0-B7EA-11B3980B81F8Q33677016-DFDDB833-0B4E-4921-9D2A-EC869F3F11ACQ33701661-DAC29F5D-75A8-41D8-84A0-674A55690FE7Q33730079-FD01E7C0-22AC-4C99-BCE1-CD535CEFA0ACQ33740152-AF0951D8-A134-4D72-A68D-1F1091D78476Q33775643-162D27D6-AF87-4AB1-A64A-3F1AB1D15F2BQ33787955-C620E0B5-107C-40EB-A3FA-F2535B412641Q33819878-81E567B2-64B4-46A0-B10A-FD20756FFAE8Q33830753-C60F9134-40FD-4D04-8B71-037178DD28AF
P2860
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Development of ranibizumab, an ...... -related macular degeneration.
@ast
Development of ranibizumab, an ...... -related macular degeneration.
@en
type
label
Development of ranibizumab, an ...... -related macular degeneration.
@ast
Development of ranibizumab, an ...... -related macular degeneration.
@en
prefLabel
Development of ranibizumab, an ...... -related macular degeneration.
@ast
Development of ranibizumab, an ...... -related macular degeneration.
@en
P2093
P1433
P1476
Development of ranibizumab, an ...... -related macular degeneration.
@en
P2093
Henry Lowman
Lisa Damico
Napoleone Ferrara
Naveed Shams
Robert Kim
P304
P356
10.1097/01.IAE.0000242842.14624.E7
P577
2006-10-01T00:00:00Z